Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
113.50    0.00 (0.00%)
Bid:
110.00
Ask:
117.00
Spread: 7.00 (6.364%)
Market Cap: £15.31m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

H1 2024 Trading Update

16 Jul 2024 07:00

RNS Number : 4931W
Itaconix PLC
16 July 2024
 

For release: 07.00, 16 July 2024

 

Itaconix plc

("Itaconix" or the "Company")

H1 2024 Trading Update

Itaconix (AIM: ITX) (OTCQB: ITXXF), a leading innovator in sustainable plant-based polymers used to decarbonise everyday consumer products, provides the following trading update for the first half of 2024.

Strategic Focus and Commercial Progress

The Company is pleased to report that the Board's expectations for FY 2024 results remain in line with those set out in the announcement of 2 April 2024.

With the strategic decision to decline low-margin business, the Company achieved unaudited revenues of $2.8 million for the first six months of 2024, compared to $4.0 million for the first half of 2023. Unaudited total gross profit margin for the first six months exceeded 38%, compared to 28% for the first six months of 2023 and 31% for FY 2023, reflecting the Company's commitment to enhance profitability. 

In addition to improving gross profit margins, the Company is diversifying its revenue base with new accounts and growth from existing accounts. Initial orders were received in the first six months for a new dish detergent application in Europe, a new sustainable leather account, and a new application in mineral processing. As previously disclosed, revenues and volume growth from these new accounts are expected to occur predominantly in H2 2024 and beyond.

The Company also continues to benefit from new orders and continuing revenues at lower levels from the existing merchandizing customer that the Company had previously taken the decision to decline low margin revenues from.

Financial Position

The Company's balance sheet remains strong, providing sufficient cash to focus on the next generation of customers, applications, and products. Net unaudited cash and investments as at 30 June 2024 were $8.0 million ($10.0 million at 31 December 2023). Cash use reflected higher finished goods inventories, higher accounts receivable in Europe, and new investments in upgrades to its facilities in Stratham, New Hampshire to support revenue growth.

This financial position is allowing the Company to target higher revenue growth and invest in new product development. The Company is seeing many exciting opportunities to develop new ingredients and increase revenues, positioning itself to better capture the commercial value of its performance ingredients.

New Product Launches

The Company launched two new products on 29 April 2024. Itaconix TSI 422, an advanced version of its leading Itaconix TSI 322 product, offers improved performance, lower overall formulation costs, and more compact formulations in cleaning applications. The Company had revenues in the first half from three customers for the use of this new polymer in two North American dish detergent brands and expects to add at least two more brands in H2 2024.

Itaconix ONZ 405, a powder version of the Company's current liquid odour neutraliser, meets customer needs in powder formulations, particularly in laundry and hygiene applications. The Company expects new revenues from this product in H2 2024.

Environmental and Regulatory Progress

The Company completed studies expanding the data on the biodegradability of its water-soluble polymers and advanced global regulatory acceptance with new approvals in China, Australia, and New Zealand. These approvals are expected to generate new revenue opportunities for current and prospective customers.

Financial Outlook

With these results for the first six months of 2024, the Board reiterates its revenue expectations of $6 million to $6.5 million and gross profit margin expectations of 36% for FY 2024.

Further details on first half results will be provided in the 2024 interim report, which the Company plans to release in early September 2024.

John R. Shaw, CEO of Itaconix, commented:

"Enhancing our revenue structure and increasing gross profit margins, while diversifying our revenue streams, pave the way for our next stage of growth. We are positioning ourselves to better capture the commercial value of our performance ingredients with new orders, new volumes in non-detergent uses, and important new product development initiatives. I believe the strategic efforts we are taking now will advance our long-term revenue growth and profitability objectives.

"We remain highly optimistic about our future and commercial progress. We are securing new detergent customers in Europe and North America and expanding the use of our performance ingredients into new applications. These efforts are focused on building a more diverse, profitable, and sustainable revenue base to achieve our goal of being a large and profitable specialty ingredient company."

-Ends-

 

Itaconix plc

John R. Shaw / Laura Denner

+1 603 775-4400

Belvedere Communications

John West / Llew Angus

+44 (0)20 7653 8702

Canaccord Genuity - Nominated Adviser and Sole Broker

Adam James / Harry Pardoe

+44 (0) 20 7523 8000

 

About Itaconix

Itaconix uses its proprietary plant-based polymer technology platform to produce and sell specialty ingredients that improve the safety, performance, and sustainability of consumer products. The Company's current ingredients are enabling and leading new generations of products in cleaning, hygiene, and beauty.

www.itaconix.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFFEIDVIELIS
Date   Source Headline
2nd Jun 20267:00 amRNSMello 2026 Presentation and Update on Trading
1st Jun 20267:00 amRNS-RProgress in Crop Production Field Trials
29th May 20267:00 amRNS-RDevelopment of Next Generation Plant-Based Paints
27th May 20267:00 amRNS-RLaunch of New Marketing Program for Detergents
14th May 20265:55 pmRNSAdjournment of AGM
6th May 20264:46 pmRNSDirector/PDMR Shareholding
27th Apr 20266:16 pmRNSTR-1
23rd Apr 20267:00 amRNSGrants of Options & PDMR dealings
24th Mar 20267:00 amRNSPreliminary Results
28th Jan 20267:00 amRNSTR-1
16th Jan 20265:29 pmRNSDirector/PDMR Shareholding
13th Jan 20267:00 amRNSFull Year Trading Update
15th Sep 20257:00 amRNSHalf Year Results
4th Sep 20257:00 amRNSNotice of Interim Results
27th Aug 20258:19 amRNSTR-1
23rd Jul 20257:00 amRNSH1 2025 Trading Update
16th Jul 20257:00 amRNS-RCroda expands agreement: sustainable odour control
1st Jul 20257:00 amRNS-RCommercial Plant-Based Product Launch
8th May 20252:20 pmRNSResult of AGM
6th May 202512:24 pmRNSTR-1
2nd May 20255:28 pmRNSNotice of AGM
1st May 20257:00 amRNSUpdate on US Tariffs
7th Apr 20257:00 amRNSGrants of Options & PDMR dealings
31st Mar 20257:00 amRNSPreliminary Results
18th Mar 20257:00 amRNSNotice of Results and Company Presentation
22nd Jan 20257:00 amRNSTrading Update
5th Nov 20247:00 amRNSTrading Update
10th Oct 20247:00 amRNSChange of Auditor
10th Sep 20247:00 amRNSHalf Year Results
2nd Sep 20247:00 amRNSNotice of Interim Results, Investor Presentation
16th Jul 20247:00 amRNSH1 2024 Trading Update
20th May 20243:03 pmRNSResult of AGM
20th May 20247:00 amRNSAGM Statement and Trading Update
29th Apr 20247:00 amRNSLaunch of two plant-based performance ingredients
19th Apr 20247:00 amRNSGrants of Options & PDMR dealings
15th Apr 20247:00 amRNSPreliminary Results and Notice of AGM
8th Apr 20247:00 amRNSNotice of Results
2nd Apr 20247:00 amRNSTrading Statement
27th Feb 20247:00 amRNSTrading Update
9th Feb 20247:00 amRNSAppointment of Non-Executive Director
26th Jan 20247:00 amRNSAppointment: Nominated Adviser and Sole Broker
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
30th Oct 20237:00 amRNSDirector/PDMR Shareholding
26th Oct 20235:28 pmRNSDirector/PDMR Shareholding
19th Oct 20235:08 pmRNSDirector/PDMR Shareholding
19th Oct 20237:00 amRNSDirector/PDMR Shareholding
5th Oct 202311:01 amRNSHoldings in Company
12th Sep 20237:00 amRNSHalf year results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.